Logo Logo

Category Archives: "INforMS"

  1. Home
  2. INforMS
  3. Page 7
May 02, 2019
MSAA recognizes ten years of artwork from individuals with multiple sclerosis
INforMS, MS Community, Partners
CHERRY HILL, N.J., May 2, 2019 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to recognize ten years of [...]
Elizabeth Porco
Read More
...25
0
Apr 30, 2019
FDA approves MAVENCLAD® (Cladribine) tablets
INforMS
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's [...]
Elizabeth Porco
Read More
...25
0
Apr 19, 2019
OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis
INforMS, Partners
PORTLAND, Ore. (KATU) – They're calling it a potential game-changer. Doctors at Oregon Health and Science University are part of a new [...]
Elizabeth Porco
Read More
...22
0
Apr 15, 2019
Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize
INforMS, Partners
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]
Elizabeth Porco
Read More
...26
0
Mar 29, 2019
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
INforMS, Partners
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
Elizabeth Porco
Read More
...25
0
Mar 27, 2019
Novartis receives FDA approval for MAYZENT (Siponimod)
INforMS, Partners
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
Elizabeth Porco
Read More
...22
0
Mar 26, 2019
Dose-finding study for SAR442168 in relapsing multiple sclerosis
INforMS
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in [...]
Elizabeth Porco
Read More
...24
0
Mar 14, 2019
BrainStorm announces first patient in phase 2 clinical trial progressive multiple sclerosis
INforMS
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE)—BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing [...]
Elizabeth Porco
Read More
...25
0
Feb 19, 2019
Depression, psychological distress symptoms affect multiple sclerosis patients’ quality of life
INforMS, MS Community
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view their well-being, [...]
Elizabeth Porco
Read More
...24
0
Dec 18, 2018
FDA accepts BrainStorm’s NurOwn® IND application for progressive multiple sclerosis
INforMS
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative [...]
Elizabeth Porco
Read More
...23
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM